Desvenlafaxine for the treatment of major depressive disorder

作者：Kornstein Susan G^*; McIntyre Roger S; Thase Michael E; Boucher Matthieu

来源：Expert Opinion on Pharmacotherapy, 2014, 15(10): 1449-1463.

DOI：10.1517/14656566.2014.923403

• adverse drug event
• desvenlafaxine
• major depressive disorder
• pharmacodynamics
• pharmacokinetics
• treatment efficacy

Introduction: Major depressive disorder (MDD) is a chronic and debilitating condition often characterized by inadequate treatment. Notwithstanding the availability of more than a dozen first-line agents across disparate classes (e. g., selective serotonin reuptake inhibitors), the majority of individuals with MDD do not achieve and sustain a recovered state. A substantial percentage of MDD patients require a treatment change due to poor efficacy or tolerability. %26lt;br%26gt;Areas covered: This review focuses on recent (%26lt;= 5 years) literature describing the pharmacokinetics, efficacy, and tolerability of desvenlafaxine, one of the more recently approved antidepressant drugs. Published papers identified via PubMed search and congress presentations were included. Results from short-term, placebo-controlled, MDD trials and randomized withdrawal trials, as well as post hoc analyses in patient subgroups, are reviewed. %26lt;br%26gt;Expert opinion: Desvenlafaxine has been shown to be an effective antidepressant with a favorable safety and tolerability profile in the general MDD population and in important patient subgroups. It has several notable differences from other serotonin-norepinephrine reuptake inhibitors, and those differences suggest populations in which it may have the most clinical benefit.

• 出版日期2014-7